Table 2 Overview of the survival characteristics of the study cohort (cases with available follow-up)
From: A comprehensive immunohistochemical analysis of IMP2 and IMP3 in 542 cases of ovarian tumors
HGSC (n = 110) | LGSC (n = 81) | mSBT (n = 27) | EC (n = 50) | CCC (n = 106) | MBT (N = 63) | MC (N = 27) | |
|---|---|---|---|---|---|---|---|
Follow-up (duration in months) | |||||||
Median | 38 | 43 | 58 | 64 | 37 | 46 | 10 |
Mean | 43 | 55 | 56 | 65 | 46 | 50 | 34 |
Max | 251 | 320 | 189 | 171 | 198 | 162 | 123 |
Survival status | |||||||
NED | 26 (23.6%) | 37 (45.7%) | 17 (63.0%) | 47 (94%) | 61 (57.5%) | 61 (96.8%) | 17 (62.9%) |
AWD | 60 (54.5%) | 24 (29.6%) | 6 (22.2%) | 2 (4%) | 19 (17.9%) | 0 (0%) | 7 (25.9%) |
DOD | 24 (21.8%) | 11 (13.6%) | 3 (11.1%) | 1 (2%) | 13 (12.3%) | 0 (0%) | 2 (7.5%) |
DTC | 0 (0%) | 1 (1.2%) | 0 (0%) | 0 (0%) | 3 (2.8%) | 0 (0%) | 0 (0%) |
DUC | 0 (0%) | 7 (8.6%) | 1 (3.7%) | 0 (0%) | 7 (6.6%) | 2 (3.2%) | 1 (3.7%) |
DOC | 0 (0%) | 1 (1.2%) | 0 (0%) | 0 (0%) | 3 (2.8%) | 0 (0%) | 0 (0%) |